Oncology & Hematology Coding Alert

Reader Questions:

Keep J9999 for Claim Before J9303 Intro

Question: A patient received Vectibix before J9303 was introduced, so we submitted the claim to Medicare with J9999. We are still getting denials for the original claim. Should we change the code? Massachusetts Subscriber Answer: Because J9303 (Injection, panitumumab, 10 mg) was not in effect on the date of service, your wisest move is to continue seeking reimbursement with J9999 (Not otherwise classified, antineoplastic drugs). Submit your appeal with the office visit notes from the day of chemotherapy (if any), the physician's order, the chemotherapy flow sheet, and the medication's NCD number. Be especially diligent about noting the date of service as the reason for reporting J9999 instead of J9303. The drug code might not be the only reason for your denial, however. Double check that you-re not submitting a non-covered diagnosis and verify that there aren't other reasons for non-payment before continuing to appeal.
You’ve reached your limit of free articles. Already a subscriber? Log in.
Not a subscriber? Subscribe today to continue reading this article. Plus, you’ll get:
  • Simple explanations of current healthcare regulations and payer programs
  • Real-world reporting scenarios solved by our expert coders
  • Industry news, such as MAC and RAC activities, the OIG Work Plan, and CERT reports
  • Instant access to every article ever published in Revenue Cycle Insider
  • 6 annual AAPC-approved CEUs
  • The latest updates for CPT®, ICD-10-CM, HCPCS Level II, NCCI edits, modifiers, compliance, technology, practice management, and more

Other Articles in this issue of

Oncology & Hematology Coding Alert

View All